Equities Analysts Offer Predictions for Replimune Group, Inc.’s Q2 2025 Earnings (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL) – Equities researchers at Roth Capital issued their Q2 2025 earnings estimates for shares of Replimune Group in a note issued to investors on Tuesday, August 27th. Roth Capital analyst B. Paluch anticipates that the company will post earnings of ($0.87) per share for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($3.08) per share. Roth Capital also issued estimates for Replimune Group’s FY2025 earnings at ($3.43) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.65) EPS, FY2027 earnings at ($2.65) EPS, FY2028 earnings at ($1.52) EPS and FY2029 earnings at ($0.40) EPS.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.10.

Several other research analysts also recently commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. HC Wainwright lifted their price target on shares of Replimune Group from $12.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Wedbush reissued an “outperform” rating and set a $16.00 price target on shares of Replimune Group in a research note on Thursday, June 6th. Barclays lifted their price target on shares of Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. Finally, Roth Mkm assumed coverage on shares of Replimune Group in a report on Tuesday. They issued a “buy” rating and a $17.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $16.20.

Replimune Group Trading Down 8.0 %

Shares of REPL opened at $10.17 on Friday. The firm’s 50 day simple moving average is $9.73 and its 200 day simple moving average is $8.17. The company has a market capitalization of $624.59 million, a P/E ratio of -3.14 and a beta of 1.25. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. Replimune Group has a 1-year low of $4.92 and a 1-year high of $21.32.

Institutional Trading of Replimune Group

Several hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its holdings in Replimune Group by 236.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock valued at $35,000 after buying an additional 2,958 shares during the period. Quest Partners LLC raised its holdings in Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after buying an additional 3,150 shares during the period. Algert Global LLC raised its holdings in Replimune Group by 5.4% during the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after buying an additional 4,340 shares during the period. Nisa Investment Advisors LLC raised its holdings in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after buying an additional 4,946 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Replimune Group by 72.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after buying an additional 4,975 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 15,881 shares of the business’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $7.50, for a total transaction of $119,107.50. Following the completion of the sale, the insider now directly owns 117,131 shares in the company, valued at approximately $878,482.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Konstantinos Xynos sold 15,881 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $7.50, for a total transaction of $119,107.50. Following the completion of the transaction, the insider now directly owns 117,131 shares in the company, valued at approximately $878,482.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. The disclosure for this sale can be found here. 20.60% of the stock is owned by insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.